Michelle Gong built a $30 million research operation - now she leads Montefiore Einstein's largest department

When COVID-19 overwhelmed New York City's hospitals in the spring of 2020, Montefiore Medical Center in the Bronx became one of the hardest-hit institutions in the country. The person coordinating the critical care response was Michelle Ng Gong, a pulmonary and critical care physician who had spent more than a decade building research infrastructure at Montefiore Einstein. The Museum of the City of New York later recognized her work during the pandemic with its Gotham Icon Award. Now, she runs the whole department.

From research director to department chair in sixteen years

Gong's appointment as permanent chair of the Montefiore Einstein Department of Medicine, announced in March 2026, follows a national search that ended where it began - with the person already doing the job. She has served as interim chair since May 2025 and first joined Albert Einstein College of Medicine in 2009 as director of research in the critical care division.

The trajectory since then has been steep. After being named chief of the division of critical care medicine in 2019 following a separate national search, Gong also took on leadership of the pulmonary medicine division the following year. Under her watch, the divisions secured $30 million in federal and foundation funding, and faculty peer-reviewed publications increased fourfold. Those are not decorative metrics. In academic medicine, they represent the difference between a division that maintains and one that grows. They also reflect something harder to quantify: the ability to recruit and retain physician-scientists in a fiercely competitive environment where every major medical center in the country is bidding for the same talent.

The dual appointment to lead both critical care and pulmonary medicine was itself unusual. These divisions operate in overlapping but distinct domains, and managing both simultaneously requires navigating different clinical cultures, different funding streams, and different faculty expectations. That she managed to grow both - rather than growing one at the expense of the other - speaks to an organizational skill set that goes beyond research productivity.

A career shaped by acute illness and large-scale trials

Gong's research focus sits at the intersection of acute respiratory failure, sepsis, and the prevention of critical illness - conditions where timing and evidence matter enormously and where the wrong clinical decision can be fatal within hours. As an NIH-funded principal investigator, she has led multiple federally funded research trials, with results published in The New England Journal of Medicine and JAMA. The National Heart, Lung, and Blood Institute recognized her with its Director's Award, one of the institute's highest honors for research leadership.

The specifics of her research portfolio reflect a consistent theme: understanding who is at risk for critical illness before they become critically ill, and developing interventions that can prevent the cascade from progressing. This is harder than it sounds. Critical care medicine has historically been reactive - patients arrive in the ICU already in crisis, and the work is stabilization and damage control. Gong's research pushes upstream, toward prediction and prevention. The trials she has led test whether specific interventions, deployed early enough, can keep patients out of the ICU entirely.

But her impact extends beyond the lab and the ICU. Gong expanded Montefiore's neuroscience ICU to support the hospital's accreditation as a comprehensive stroke center - a designation that requires meeting rigorous standards for neurological emergency care and affects which patients are transported to the hospital and which are diverted elsewhere. She launched a robotic bronchoscopy program and collaborated with colleagues to dramatically increase lung cancer screening and diagnosis rates. These are the kinds of clinical infrastructure investments that do not generate headlines but shape outcomes for thousands of patients. A hospital that screens more effectively for lung cancer catches tumors earlier. A hospital with robotic bronchoscopy can biopsy lesions that were previously inaccessible. The downstream effects compound over years.

Leading the world's largest respiratory medicine society

Beyond Montefiore Einstein, Gong was elected president of the American Thoracic Society, which represents more than 30,000 members across 133 countries. It is the world's leading professional society for respiratory health - a role that places her at the center of global conversations about pulmonary disease, critical care standards, environmental lung health, and health policy. The ATS presidency is not ceremonial. The society publishes major research journals, sets clinical practice guidelines, and advocates for research funding and public health policy. Leading it while simultaneously running a major academic department requires operating at two very different organizational scales.

Her academic pedigree is correspondingly dense. A bioengineering degree from the University of Pennsylvania. Medical degree from Yale. Internal medicine residency at Beth Israel Hospital in Boston. A combined clinical and research fellowship in pulmonary and critical care medicine at Harvard, where she also earned a master's degree in epidemiology from the Harvard School of Public Health while serving as an instructor at Harvard Medical School. She was on the faculty at Mount Sinai School of Medicine from 2004 before moving to Montefiore Einstein in 2009.

The Bronx context shapes the mandate

Montefiore Health System serves approximately three million people across the Bronx, Westchester, and the Hudson Valley. The system operates 10 hospitals, including the Children's Hospital at Montefiore and Burke Rehabilitation Hospital, along with more than 200 outpatient ambulatory care sites. The Bronx remains one of the poorest urban counties in the United States, with disproportionately high rates of chronic disease, respiratory illness, and health system distrust. Leading a department of medicine in this setting is not the same as leading one at a well-resourced suburban academic center. The patient population is sicker, the social challenges are steeper, and the gap between what medicine can offer and what communities can access is wider.

Gong has acknowledged this context directly. "I look forward to advancing our exceptional clinical care, research discoveries, and tremendous training programs to improve health in our community," she said in the announcement. The emphasis on community is not incidental. At Montefiore, the department's mission is inseparable from the demographics it serves. The Bronx has some of the highest asthma hospitalization rates in the country, elevated rates of diabetes-related complications, and a population that experienced among the worst COVID-19 mortality in the nation. These are not abstract health statistics for a pulmonary and critical care specialist who built her career at this institution. They are the clinical reality that walks through the door every day.

What the appointment does not resolve

Personnel announcements are, by their nature, optimistic documents. They catalog accomplishments and signal institutional confidence. What they do not convey is the difficulty of the job ahead. Academic medical departments across the country face mounting pressures: declining NIH funding in real terms, physician burnout that accelerated during the pandemic and has not fully subsided, the challenge of training the next generation of physician-scientists who increasingly weigh academic careers against more lucrative private-sector alternatives, and the constant tension between clinical revenue generation and research mission.

Gong's track record suggests she understands these pressures. Building a research operation from a small base to $30 million in funding requires not just scientific talent but organizational skill - the ability to recruit, retain, and support faculty in an environment where competing institutions are always recruiting. Whether she can sustain that growth trajectory at the department level, across a much larger portfolio of divisions and specialties, is the question her tenure will answer.

Albert Einstein College of Medicine receives approximately $200 million annually from the NIH and houses six NIH-funded research centers, spanning cancer, intellectual and developmental disabilities, clinical and translational research, AIDS, and two in diabetes. The Department of Medicine is its largest clinical and academic unit. Gong now has the mandate to shape both its research direction and its clinical footprint in a borough that needs both desperately.